CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 190 enrolled
Drug / intervention
G238 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01993823
NCT01993823Phase 3Completed

A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Active Treatment-controlled Study Assessing the Safety and Efficacy of G238 Compared to Clotrimazole 1% Otic Solution in Patients With Otomycosis

Salvat·interventional·Posted Nov 25, 2013·Updated Apr 4, 2017

In Brief

A Phase 3 clinical trial evaluating G238 and Clotrimazole for Otomycosis. Completed, enrolled 190 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of G238 for the treatment of otomycosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOtomycosis
CountriesSpain
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 25, 2013
Enrollment StartMay 1, 2013
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 12.6 years ago

Interventions

G238drug

Five drops into the ear canal twice daily for 14 days

Clotrimazoledrug

Five drops into the ear canal twice daily for 14 days